BioRestorative Completes Dosing in Phase 2 Trial of BRTX-100 to Treat Chronic Lumbar Disc Disease; Shares Rise
[출처/시간] MT Newswires - 11:38 AM ET, 05/26/2026 11:38 AM EDT, 05/26/2026 (MT Newswires) -- BioRestorative Therapies (BRTX) said Tuesday it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease. The move advances the study into the next stage of blinded follow-up before planned topline safety and efficacy results in Q2 2027, the company said. The trial enrolled about 99 people in the US and is designed
뉴스|admin|May 26, 2026
[출처/시간] MT Newswires - 11:38 AM ET, 05/26/2026
11:38 AM EDT, 05/26/2026 (MT Newswires) -- BioRestorative Therapies (BRTX) said Tuesday it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease.
The move advances the study into the next stage of blinded follow-up before planned topline safety and efficacy results in Q2 2027, the company said.
The trial enrolled about 99 people in the US and is designed to assess the safety and preliminary efficacy of BRTX-100 in people with painful chronic lumbar disc disease, BioRestorative said.
ADVERTISEMENT
The company said it is continuing phase 3 trial readiness projects following Type B meeting alignment with the US Food and Drug Administration.
BioRestorative shares were up 20% in Tuesday late morning trading.
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.